MiniMed Smart MDI trial links higher alert response to 8.1-point Time in Range gain, 0.6-point HbA1c drop
MMED•MiniMed presented six-month randomized trial results linking higher response to Smart MDI alerts with an 8.1-percentage-point Time in Range gain and a 0.6-percentage-point HbA1c drop.
1. Trial results
MiniMed said higher alert engagement among people using its connected insulin pen system was linked to better glucose control. A real-world analysis of more than 5,500 users also tied frequent alert responses to better control; no severe hypoglycemia or diabetic ketoacidosis was reported in the Smart MDI arm during the study.
